CervoMed

Q3 2025 Q2 2025 Q1 2025 Q4 2024 +3.20%Q3 2024 -7.58%Q2 2024 +32.98%Q1 2024 -1.38%Q4 2023 -4.89%Q3 2023 -2.64%Q2 2023 -1.05%Q1 2023 -5.42%Q4 2022 -8.73%Q3 2022 +21.45%Q2 2022 -2.00%Q1 2022 +18.57%Q4 2021 -3.70%Q3 2021 -6.67%Q2 2021 -7.02%Q1 2021 0.00%Q4 2020 +4.90%Q3 2020 -10.13%Q2 2020 -0.91%Q1 2020 +39.34%Q4 2019 -8.82%Q3 2019 -27.63%Q2 2019 -0.92%Q1 2019 -4.87%Q4 2018 +3.83%Q3 2018 0.00%Q2 2018 +2.78%Q1 2018 -3.64%Q4 2017 -3.64%Q3 2017 -3.65%Q2 2017 -7.74%Q1 2017 -0.56%Q4 2016 -0.56%Q3 2016 -3.81%Q2 2016 0.00%Q1 2016 +11.11%Q4 2015 -6.36%Q3 2015 -9.09%Q2 2015 +1.21%Q1 2015 -2.00%Q4 2014 -7.14%Q3 2014 -1.11%Q2 2014 +4.50%Q1 2014 -3.23%Q4 2013 0.00%Q3 2013 0.00%Q2 2013 0.00%Q1 2013 0.00%Q4 2012 +18.75%Q3 2012 +4.76%Q2 2012 -2.56%Q1 2012 0.00%Q4 2011 +8.00%Q3 2011 -11.48%Q2 2011 +7.14%Q1 2011 +5.45%Q4 2010 +1.56%Q3 2010 +19.05%Q2 2010 -12.04%Q1 2010 0.00%

Aug 12, 2024

•

Jun 30, 2024

CervoMed Q2 2024 Earnings Report

Reported second quarter financial results and provided corporate updates.

Key Takeaways

CervoMed reported its financial results for the second quarter ended June 30, 2024, highlighting the completion of enrollment in the RewinD-LB Phase 2b trial and remaining on track to report topline data in December 2024. The company's cash position was strong due to a private placement, providing runway through 2025.

Completed enrollment in RewinD-LB Phase 2b clinical trial in June 2024, with topline data expected in December 2024.

Hosted a virtual key opinion leader event in July 2024, highlighting neflamapimod’s potential for patients with early-stage DLB.

Completed a private placement for up to $149.4 million in April 2024, extending cash runway through 2025.

Added to the Russell 2000® and Russell 3000® Indexes effective July 1, 2024.

Previous year: -$1.04

-74.0%

R&D expenses (Q2)

$3.77M